文献速递细菌感染、耐药与抗菌药物结核与非结核分枝杆菌

2001至2015年法国诊断麻风病例抗菌药物耐药性的前瞻性研究

Prospective study on antimicrobial resistance in leprosy cases diagnosed in France from 2001 to 2015.
PubMed 文献 · Clin Microbiol Infect · 2018-06-12

该研究对2001至2015年法国本土及法属领地诊断的麻风患者前瞻性检测rpoB、folP1和gyrA基因突变以评估耐药。334份皮肤活检中184份(55.1%)麻风分枝杆菌阳性,对应160例多菌型病例;18例(11.3%)检出耐药,其中氨苯砜耐药13例(8.1%)、利福平耐药3例(1.9%)、氧氟沙星耐药2例(1.3%),无多重耐药株;新发病例与复发病例耐药比例分别为9/127(7.0%)和9/33(25.7%),差异有统计学意义(p 0.003)。

要点

  • 160例多菌型麻风病例中18例(11.3%)检出耐药,以氨苯砜耐药为主(13例,8.1%)。
  • 复发病例耐药比例9/33(25.7%)高于新发病例9/127(7.0%),p 0.003。
  • 未发现多重耐药株;耐药检测有助于个体治疗及流行病学调查。

核心结论

  • 这是欧洲首次报告新发和复发麻风病例的抗菌药物耐药监测,检出耐药有助于个体治疗和流行病学调查。

研究设计与样本

  • 前瞻性研究纳入2001至2015年法国本土或法属领地诊断的麻风患者,对多菌型病例通过分子检测rpoB、folP1和gyrA突变评估耐药。
  • 共接收334份疑似麻风皮肤活检样本,184份(55.1%)麻风分枝杆菌阳性,对应160例多菌型病例。

主要发现

  • 160例多菌型病例中18例(11.3%)检出耐药:氨苯砜耐药13例(8.1%)、利福平耐药3例(1.9%)、氧氟沙星耐药2例(1.3%),无多重耐药株。
  • folP1突变包括P55L(n=7)、T53I(n=5)、T53A(n=1);rpoB突变包括S456L(n=2)、S456F(n=1);gyrA突变为A91V(n=2)。
  • 新发病例耐药9/127(7.0%)vs 复发病例9/33(25.7%),差异有统计学意义(p 0.003)。
  • 耐药株SNP1-4型分布为2、1、12、3例,其中新喀里多尼亚5例SNP3病例携带相同T53I FolP1替换。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antimicrobial resistance (AMR) in leprosy is mostly unknown because Mycobacterium leprae does not grow in vitro and bacteriologic investigations have been abandoned. However, molecular detection of resistance can be applied to multibacillary cases. Patients living in France mainland or in the French territories and diagnosed with leprosy from 2001 to 2015 were prospectively studied for AMR by detecting mutations in rpoB for rifampicin resistance, in folP1 for dapsone and in gyrA for ofloxacin. Single nucleotide polymorphism (SNP) genotypes 1-4 were determined for resistant strains. Of 334 skin biopsy samples received for suspicion of leprosy, 184 (55.1%) were positive for M. leprae (acid-fast bacilli and M. leprae-specific repetitive element PCR) corresponding to 160 multibacillary cases. AMR was detected in 18 cases (11.3%): 13 cases (8.1%) of dapsone resistance, three (1.9%) rifampicin and two (1.3%) ofloxacin. There were no strains with multidrug resistance. The mutations (numbering system of M. leprae TN strain genome) found were P55L (n = 7), T53I (n = 5), T53A (n = 1) in folP1; S456L (n = 2) and S456F (n = 1) in rpoB; and A91V (n = 2) in gyrA. Resistance proportion differ significantly between new and relapse cases (9/127, 7.0%, vs. 9/33, 25.7%, p 0.003). The frequency distribution of SNP1-4 types of resistant strains was two, one, 12 and three with five SNP3 cases from New Caledonia harbouring the same T53I FolP1 substitution. This is the first report of AMR surveillance for new and relapse cases of leprosy in Europe. Detection of resistance helped in individual treatment as well as in epidemiologic investigations.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Chauffour A, Lecorche E, Reibel F, et al. Prospective study on antimicrobial resistance in leprosy cases diagnosed in France from 2001 to 2015. Clin Microbiol Infect. 2018. PMID: 29906598. doi:10.1016/j.cmi.2018.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。